AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 AUG 23 - (NewsRx Network) -- The benefits of adjuvant chemotherapy for breast cancer outweigh its side effects, especially for younger women, conclude authors of a study in the July 28, 2001, issue of the Lancet.
Previous randomized trials have shown that prolonged chemotherapy for breast cancer substantially reduces the risk of disease relapse and death compared with no chemotherapy. However, toxic side effects are a concern because they may result in decreased quality of life for patients; it is therefore important to determine whether the benefits of chemotherapy are sufficient to offset its side effects and justify its use, both overall, and within specific subgroups of patients.
Bernard Cole from Dartmouth Medical School, Lebanon, New Hampshire, and colleagues did a statistical analysis, using data from 47 randomized trials involving about 18,000 women, to measure the benefits of chemotherapy in terms of survival time adjusted for the quality of life experienced. The investigators used a statistical method called Q-TWiST (Quality-adjusted Time Without Symptoms of disease or Toxicity of treatment) to compare women treated with chemotherapy with women not given chemotherapy. Their analysis considered three major health states experienced by patients: (1) time with chemotherapy, (2) time following chemotherapy and before disease relapse, and (3) time following disease relapse. They weighted the duration of each health state based on a valuation of quality of life, and summed the weighted durations to produce a measure called quality-adjusted survival.
Within 10 years' follow-up the benefit of increased relapse-free and overall survival for younger women (aged younger than 50 years) who received chemotherapy balanced the burdens in terms of acute toxic side effects, especially among women enrolled in trials that did not include tamoxifen treatment. Overall, chemotherapy-treated younger women gained an average of 10.3 months ...
Source: HighBeam Research, Study Reports Benefits Outweigh Burden Of Chemotherapy.(adjuvant...